Large Device Firms Thrive, Smaller Ones Dive, Post-Device Tax, GAO Says
This article was originally published in The Gray Sheet
Executive Summary
Large device firms have thrived since the Affordable Care Act implementation applied a 2.3 percent excise tax to their sales, but medium- and small-size firms did less well, says a July 30 General Accountability Office report. But GAO did not draw a causal link between ACA, the tax, and profits.
You may also be interested in...
Industry Groups Tag-Team To Attack Device Tax
AdvaMed and MDMA simultaneously released survey results from their member companies arguing the tax has hurt jobs and investment in the industry and will continue to do so if it is not repealed.
Industry Looking To New GOP Congress To Repeal Device Tax
AdvaMed says a new Congressional Research Service report underestimates the number of people likely to lose their jobs because of the tax and is looking forward to a new Republican Congress focused on repealing it.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”